PRESS RELEASE

AMOEBAannounces that the decision of the US EPA on the registration of the biocidal active substance is expected to take place at the end of August 2019

Lyon (France), June 19th, 2019 -AMOEBA (FR0011051598 - AMEBA), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and a biocontrol product for plant protection, announces that the decision of the US Environmental Protection Agency (EPA) on the registration of the biocidal active substance is expected to take place at the end of August 2019

As a reminder, in March 2019, the EPA informed the Company that the scientific review was still ongoing (refer to press release of March 28, 2019).

On June 18, 2019, the EPA informed the Company that the final decision would be notified to the Company before the end of August 2019.

As soon as the EPA's decision is known, Amoéba will release this information through a press release.

About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1)on a global chemical biocide market for water treatment, evaluated at €21Bn (2)and on the biocontrol market for plant protection estimated globally at €1.6Bn (4). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (3)in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba- biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets

(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

1

Contacts:

Amoéba

Investors Relations

Medias relations

Valérie FILIATRE

Grégory BOSSON

Constance LOZET

General Manager

Agence Calyptus

Agence Ekno

+33 (0)4 26 69 16 00

+33(0)1 53 65 37 90

+33(0)7 78 41 19 70

valerie.filiatre@amoeba-biocide.com

gregory.bosson@calyptus.net

constance.lozet@ekno.fr

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 27, 2018 (a copy of which is available on www.amoeba-biocide.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.

2

Attachments

  • Original document
  • Permalink

Disclaimer

Amoéba SA published this content on 19 June 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 June 2019 19:53:06 UTC